ALEXANDRIA, Va., Nov. 6 -- United States Patent no. 12,458,674, issued on Nov. 4, was assigned to Massachusetts Institute of Technology (Cambridge, Mass.).
"M13 phage based gene therapy platform" was invented by Uyanga Tsedev (Somerville, Mass.) and Angela M. Belcher (Lexington, Mass.).
According to the abstract* released by the U.S. Patent & Trademark Office: "An engineered phage-derived particle (PDP) for expressing a transgene in a target cell transduced with a bacteriophage, the PDP includes (i) less than about 500 bp of DNA from the bacteriophage genome, (ii) an ITR-flanked therapeutic gene up to 20 kb, (iii) an endosomal escape sequence, (iv) a nuclear localization sequence, and (v) a cell-specific targeting moiety. The PDP may esca...